Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting

Phase 2

Completed

Conditions: Cardiopulmonary Bypass
Reperfusion Injury
Coronary Artery Bypass Grafting

Interventions: Drug: Placebo Oral Tablet
Drug: Periostat

Registration Number: NCT00246740

Lead Sponsor: University of Alberta

Brief Summary: The purpose of this study is to determine whether doxycycline (Periostat) at a sub-antimicrobial dose will decrease reperfusion injury after coronary artery bypass grafting (CABG) surgery with cardiopulmonary bypass (CPB).

Detailed Description: This proposal is for a randomized, placebo-controlled, double-blinded study of the use of doxycycline in patients requiring CABG surgery. Patients will be randomized 1:1 to receive either doxycycline or placebo.

This study will be conducted in a blinded manner. The pharmacy will randomize patients and will have the randomization code. The code will only be broken in the case of an emergency and the event will be fully documented.

In addition to standard care, patients will receive oral administration of 20 mg of doxycycline or placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.

Myocardial atrial biopsies will be taken at 2 time points during the CABG procedure: during cannulation of the right atrium and 10 minutes after cross-clamp release. Tissue will be analyzed for MMP-2 and -9 activity and TnI and MLC-1 levels.

A Swan-Ganz-Catheter will be placed in the pulmonary artery over 24 hours to measure hemodynamics (LVSWI).

A coronary sinus catheter will be placed under echocardiographic guidance prior to initiation of CPB (will be removed 20 minutes after cross-clamp release).

Patients will have an additional ECG on post-operative days 1 and 3.

Additional blood will be drawn to determine doxycycline plasma levels, MMP-2 and -9 activity, total gelatinolytic activity, and levels of troponin I and T products at the following time points: pre-induction, prior to initiation of CPB, 10 and 20 minutes following the release of the aortic cross clamp (arterial and venous) and 3, 6, 24 and 72 hours post aortic cross clamp removal (venous). Each of the above samples will require 6 mL of blood for a study total of 72 mL. At the time of each blood draw we will measure and record the hematocrit value.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 56

Inclusion Criteria

Written informed consent
Aged 18 through 80 years, inclusive
Scheduled for primary CABG surgery with CPB

Exclusion Criteria

Females of childbearing potential
Emergency CABG
Previous sternotomy
Planned simultaneous surgery (i.e. valve repair or carotid endarterectomy)
Myocardial infarction within 48 hours
Pre-operative atrial fibrillation
Pre-operative ventricular pacing or left bundle branch block (LBBB)
Known hypersensitivity to tetracycline class antibiotics
Renal failure requiring dialysis

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo oral tablet	Placebo Oral Tablet	Patients received oral administration of matching placebo pills, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
Periostat	Periostat	Patients received oral administration of 20 mg of doxycycline, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).

Primary Outcome Measures

Name	Time	Method
Left Ventricular Stroke Work Index (LVSWI)	Before surgery up to 24h of reperfusion	Measure of global left ventricular function. The formula used for calculation is: LVSWI= SI x MAP x 0.0144 LVSWI = Left Ventricular Stroke Work Index (g\*m/m2) SI = Stroke Index (mL/beat/m2) MAP = Mean Arterial Pressure (mmHg) 0.0144 is a conversion term to equalize units.

Secondary Outcome Measures

Name	Time	Method
Cleaved TroponinI/GAPDH Ratios in Right Atrial Biopsy	Before surgery and 10 minutes reperfusion after surgery	Measurement of the ratios of cleaved TnI (troponin-I) versus GAPDH in biopsies collected from right atria. Measure is the ratio TnI/GAPDH
Cardiac Matrix Metalloproteinase-9 Activity in Right Atrial Biopsies at 10 Minutes Reperfusion	Before surgery and 10 minutes reperfusion after surgery	Biochemical activity of MMP-9 activity in right atrial biopsies, measured at 10 minutes of reperfusion after surgery. To determine MMP-9 activity, 20 μg of total protein from both myocardial extracts and plasma were analyzed by gelatin zymography. For detailed methodology consult Cheung PY, Sawicki G, Wozniak M, et al: Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000; 101:1833-1839
Cardiac Matrix Metalloproteinase-2 Activity in Right Atrial Biopsies at 10 Minutes Reperfusion	Before surgery and 10 minutes reperfusion after surgery	Biochemical activity of MMP-2 activity in right atrial biopsies, measured at 10 minutes of reperfusion after surgery.
Venous Plasma Concentration of C-reactive Protein	Before surgery and up to 72 h reperfusion after surgery	Measurement of inflammation marker C-reactive protein in plasma
Venous Plasma Concentration of IL-6	Before surgery and up to 72 h reperfusion after surgery	Measurement of inflammation marker interleukin-6 in plasma
Venous Plasma Cardiac Matrix Metalloproteinase-2 Activity Before and After Reperfusion	Before surgery and up to 72 h reperfusion after surgery	Biochemical activity of MMP-2 activity in venous plasma, measured before surgery and up to 72h of reperfusion after surgery.
Venous Plasma Cardiac Matrix Metalloproteinase-9 Activity Before and After Reperfusion	Before surgery and up to 72 h reperfusion after surgery	Biochemical activity of MMP-9 activity in venous plasma, measured before surgery and up to 72h of reperfusion after surgery.
Venous Plasma Concentration of Troponin-I	Before surgery and 10 minutes reperfusion after surgery	Measurement of levels of TnI (troponin-I), a marker of cardiac cell damage